CAR-T in China
CAR-T in China for international patients
9 min read · Last verified: 2026-07-30
Why international patients look at China
CAR-T cell therapy re-engineers a patient’s own T cells to recognize and kill cancer cells. For relapsed or refractory blood cancers — multiple myeloma, B-cell lymphomas, B-cell acute lymphoblastic leukemia — it can produce remissions after other treatments have failed.
China has become a serious option for international patients for three documented reasons:
- Cost. Approved CAR-T products list at roughly ¥1.0–1.3 million (about $140,000–180,000), versus $373,000–475,000 list prices in the United States — before insurance.
- Capacity. China runs one of the world’s largest CAR-T clinical programs, with experience concentrated in a small number of high-volume centers.
- Access. Where some countries restrict CAR-T to narrow indications, Chinese centers treat a broader range of relapsed/refractory patients, within their own protocols.
None of this makes China the right choice for every patient. Distance from your home care team, the intensity of the first weeks after infusion, and the need for long-term monitoring are real constraints.
Two routes: commercial treatment and clinical trials
Commercially approved products. Six CAR-T products are approved by China’s NMPA, covering BCMA and CD19 targets. Commercial treatment is the predictable route: known product, known process, known price list.
Clinical trials. China also runs a large trial pipeline. Trials can mean access to newer targets at lower cost, but eligibility is strict, waiting lists exist, and some marketed “trials” are not what they claim. Our clinical trials page explains how to verify a trial is registered and what foreigner eligibility actually looks like.
What hospitals need before they can answer you
Chinese hospitals review international cases on documents. A credible review requires, at minimum: a pathology report with exact subtype, biomarker results, a dated treatment history, recent imaging and labs, and performance status. Missing or untranslated items are the most common reason reviews stall.
This is the problem Kaimen exists to solve: the Medical Case organizes your records with every fact linked to its source, and the Case Passport turns them into the bilingual summary a review team expects. See how to prepare your case.
A realistic timeline
From first contact to infusion, well-prepared patients typically see:
- Case review: days to a few weeks, depending on record completeness.
- Remote consultation and quotation: one to two weeks.
- Visa and travel: two to four weeks, driven by consular processing.
- Cell collection, manufacturing, bridging therapy: three to five weeks in-country.
- Infusion and monitoring: two to four weeks in-country, with the highest-risk window in the first days after infusion.
- Return-home handoff: a bilingual discharge package for your home oncology team.
Total time in China is commonly six to ten weeks. Timelines move with your disease status — which is why treating teams, not websites, make the final calls.
The honest limitations
- CAR-T is demanding treatment. Cytokine release syndrome and neurotoxicity require a hospital equipped to manage them.
- It does not work for everyone. Response rates in published studies vary by product and indication.
- Follow-up is long. You return home with a monitoring plan your local team must accept — involve them early.